UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents • any disruption in the operations of the third-party providers who host our software solutions or any limitations on their capacity or interference with our use; • our ability to r ...

We outsource substantially all of the infrastructure relating to our hosted software solutions to third-party hosting services. Customers of our hosted software solutions need to be able to access our software platform at any time, without interruption or degradation of performance, and we provide them with service-level commitments with respect to uptime. Our hosted software solutions depend on protecting the virtual cloud infrastructure hosted by third-party hosting services by maintaining its configurati ...

Certara Inc. (NASDAQ:CERT) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO Andrew Schemick - CFO Conference Call Participants Dave Windley - Jefferies Max Smock - William Blair Luke Sergott - Barclays Joe Vruwink - Baird Wolf Chanoff - Bank of America Lu Li - Credit Suisse Operator Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a liste ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39799 Certara, Inc. (Exact name of registrant as specified in its charter) Delaware 82-2180925 (State or ...

Financial Data and Key Metrics Changes - The company reported second quarter revenue of $82.8 million, growing 18% year-over-year on a reported basis and 21% on a constant currency basis [9][23] - Adjusted EBITDA for the second quarter of 2022 was $28 million, compared to $25.5 million for the second quarter of 2021, representing 9% growth [37] - Net loss for the second quarter of 2022 was $0.6 million compared to a net loss of $2.9 million in the second quarter of 2021 [36] Business Line Data and Key Metrics Changes - Software revenue was $28.7 million, growing 48% year-over-year on a constant currency basis, with a 92% aggregate renewal rate [11][25] - Technology-driven services revenue was $54 million, representing a 10% growth on a constant currency basis compared to the second quarter of last year [16][28] - Regulatory services growth was flat, and the company is no longer forecasting it to grow at historical rates for the remainder of the year [29][19] Market Data and Key Metrics Changes - Trailing 12 months bookings came in at $393.5 million, up approximately 25% year-over-year on a reported basis [24] - The company experienced a slowdown in regulatory services due to delays in projects and recent regulatory decisions affecting Chinese customers [18][19] - The biosimulation services revenue continues to show robust growth in the high teens on a constant currency basis [16][29] Company Strategy and Development Direction - The company is committed to expanding the role of biosimulation to meet the needs of researchers, with new product launches such as the Simcyp Discovery Simulator [12][21] - There is a focus on investing in the team to expand existing customer relationships and establish new ones, particularly in biosimulation [17][21] - The company is adjusting its revenue guidance for the full year to $325 million to $335 million, reflecting a reduction due to foreign exchange and regulatory services performance [19][40] Management's Comments on Operating Environment and Future Outlook - Management noted that the regulatory services business has experienced more volatility than planned, and they are taking a more conservative outlook for the remainder of the year [18][19] - The company remains optimistic about the growth in biosimulation and Pinnacle 21, with opportunities to expand offerings throughout the drug development cycle [21][39] - Management expressed confidence in the company's ability to capitalize on opportunities despite challenges in the regulatory services segment [21][78] Other Important Information - The company ended the quarter with $194.8 million of cash and cash equivalents and had $299 million of outstanding borrowings under its term loan [38] - Adjusted diluted earnings per share for the second quarter of 2022 was $0.09, compared to $0.07 for the second quarter of 2021 [37] Q&A Session Summary Question: Visibility on Regulatory Services - Management indicated that visibility varies by client, with about 60% visibility on project start dates [46][47] Question: Update on Biologics Simulator and Pinnacle 21 - The biologics simulator is growing, and Pinnacle 21 is tracking well with early sales from new product launches [50][52] Question: Headwinds from Chinese Customers - The headwind is specific to the regulatory business, but there are opportunities for biosimulation to address concerns about diversity in submissions [54] Question: Length of Sales Cycle - The sales cycle typically runs a couple of quarters, with strong bookings on the biosimulation side despite challenges in regulatory [62][65] Question: Adjusted EBITDA Margin - The adjusted EBITDA margin was impacted by lower revenues and investments in corporate functions, with expectations for a more even margin through the back half of the year [71][73]

Table of Contents | --- | --- | --- | --- | |------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------- ...

Accelerating Medicines May 2022 Disclaimer Disclaimer The following presentation has been prepared by Certara, Inc. ("we", "us", or "the Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be ...

Certara, Inc. (NASDAQ:CERT) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants David Deuchler – Investor Relations William Feehery – Chief Executive Officer Andrew Schemick – Chief Financial Officer Conference Call Participants Dave Windley – Jefferies Wolf Chanoff – Bank of America Vikram Purohit – Morgan Stanley Justin Lin – William Blair Jacob Putman – Barclays Vikram Kesavabhotla – Baird Operator Good day, and thank you for standing by. Welcome to the Certara First Quarter 2022 ...

Table of Contents | --- | --- | --- | --- | |---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------- ...

Certara, Inc. (NASDAQ:CERT) Q4 2021 Earnings Conference Call March 1, 2022 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO Andrew Schemick – CFO Conference Call Participants Luke Sergott - Barclays John Kreger - William Blair Dave Windley - Jefferies Michael Ryskin - Bank of America Vikram Kesavabhotla - Baird Operator Good day and thank you for standing by. Welcome to the Certara Fourth Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode ...